comprehensive -WSS

comprehensive

author：knowledge 2025-10-01 11:02:32 - browse：9132

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Decaf coffee targeted by food safety group under obscure FDA rule

focus

entertainment

WSS

Covid vaccine financial winners and losers, from Pfizer to Novavax

Steward Health Care has deal to sell doctor network to UnitedHealth

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

FDA's naming rule on biosimilars has undermined competition

Abortion pill case raises question: who can sue the FDA?

Abortion pill Supreme Court ruling could impact entire drug industry

leisure time

comprehensive

entertainment

23andMe had bad news about my health. I wish a person had delivered it

What nurses really want: sufficient staffing for patient care

Affirmative action in medical school literally saved lives

Elevance, private equity launch primary care company

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Eliminate the waiting period for sterilization covered by Medicaid

In Memoriam: Notable people who died in 2023

Merck drug for rare lung condition set for approval in U.S.

Moonlake's readout produced a cash windfall. Risks remain

Supreme Court mifepristone arguments center on docs' right to sue

leisure time

Covid vaccine financial winners and losers, from Pfizer to Novavax

CDC wastewater surveillance dashboard to track bird flu hotspots

Patient advocates debate FDA's accelerated approval process

What nurses really want: sufficient staffing for patient care

Researchers on aging grapple with how to calculate biological age

Abortion pill case raises question: who can sue the FDA?

knowledge

focus

entertainment

knowledge